A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
The primary objective of the study is to assess the safety and tolerability of meropenem-vaborbactam administered by intravenous (IV) infusion in children 3 months and above to less than 12 years with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP)
Epistemonikos ID: 896b01e3aa94d779ae1d2bd4eea262e466cd7b84
First added on: Dec 01, 2024